Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:35 PM
Ignite Modification Date:
2025-12-24 @ 6:35 PM
NCT ID:
NCT00788957
Eligibility Criteria:
Inclusion Criteria:
* metastatic adenocarcinoma of the colon or rectum
* wild-type KRAS tumor status
* radiographic evidence of disease progression during or following treatment with irinotecan and/or oxaliplatin containing chemotherapy for mCRC
* measurable disease \>/= 20 mm per Response Evaluation Criteria In Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* adequate laboratory values
Exclusion Criteria:
* history of central nervous system (CNS) metastases
* history of another primary cancer, unless:
* curatively resected non-melanomatous skin cancer
* curatively treated cervical carcinoma in situ
* other primary solid tumor treated with curative intent and no known active disease present for \>/= 5 years
* prior treatment with an anti-epithelial growth factor receptor (EGFR), hepatocyte growth factor receptor (HGFR, c-MET), and/or insulin-like growth factor receptor (IGFR) inhibitor
* prior treatment with AMG 102 or AMG 479
* prior treatment with chemotherapy or radiotherapy \</= 21 days
* prior treatment with targeted therapy \</= 30 days
* known allergy or hypersensitivity to panitumumab, AMG 102, or AMG 479
* history of interstitial lung disease
* clinically significant cardiovascular disease \</= 1 year
* active inflammatory bowel disease
* known human immunodeficiency virus (HIV), hepatitis C, or hepatitis B infection
* any co-morbid disease or condition that could increase the risk of toxicity
* serious or non-healing wound \</= 35 days
* any uncontrolled concurrent illness or history of any medical condition that could interfere with the interpretation of the study results
* major surgical procedure \</= 35 days or minor surgical procedure \</= 14 days
* other investigational procedures or drugs \</= 30 days
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00788957
Study Brief:
Protocol Section:
NCT00788957